Domestic pharma industry revenues expected to grow 6-8 percent next fiscal: Rating agency ICRA
In terms of emerging trends in the industry, e-pharmacies have gained significant traction in recent years and now account for 10-15 percent of the IPM currently, it added.
New Delhi: Domestic pharmaceutical industry is expected to witness a revenue growth of 6-8 percent in the next fiscal, rating agency ICRA said on Thursday. Despite several disruptive events, the Indian pharmaceutical market (IPM) witnessed a healthy CAGR of 10.9 percent between FY2012 and FY2022.
"Going forward, ICRA expects revenues for its sample set to increase by 6-8 percent in FY2024 against 3-4 percent growth in FY2023," ICRA Assistant Vice President & Sector Head - Corporate Ratings Mythri Macherla said in a statement.
Structural factors such as ageing population and continued rise in lifestyle/chronic diseases, in addition to WPI-linked price hikes for NLEM products, new product introductions, and annual price hikes for non-NLEM products, are expected to support revenue growth for the industry, she added.
Since FY2018, IPM growth has largely been supported by price increases and new product introductions, even as volume growth remained between 2-3 percent each fiscal, Macherla said. Higher sales of anti-infectives, further supported by price increases taken to offset raw material cost inflation, aided the overall IPM growth of 14.6 percent in FY2022, she added.
However, given the high base, the volume contracted by 1.2 percent for the nine-month period of FY2023, ICRA said.
The steps being taken by the companies towards new product introductions and enhancements in field force are expected to support their growth going forward, it added. ICRA noted that drugs listed under National List of Essential Medicines (NLEM) accounted for 17-18 percent of the IPM, with some companies deriving around 30 percent of their revenues from such medications. In terms of emerging trends in the industry, e-pharmacies have gained significant traction in recent years and now account for 10-15 percent of the IPM currently, it added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.